808 results
6-K
EX-99.2
SNY
Sanofi
2 May 24
Current report (foreign)
3:52pm
), and warm autoimmune hemolytic anemia (phase 2b results in H2 2024).
About Sanofi
We are an innovative global healthcare company, driven by one
6-K
EX-99.4
SNY
Sanofi
2 May 24
Current report (foreign)
3:52pm
previous RSV seasons. This achievement is the result of the exemplary pragmatic collaboration among scientists, industry, healthcare providers … policymakers, healthcare providers and parents who share our collective ambition to safeguard babies from RSV disease.”
NIRSE-GAL is a large
6-K
EX-99.3
SNY
Sanofi
2 May 24
Current report (foreign)
3:52pm
healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated
6-K
EX-99.1
SNY
Sanofi
2 May 24
Current report (foreign)
3:52pm
information on frexalimab clinical trials, please visit www.clinicaltrials.gov.
About Sanofi
We are an innovative global healthcare company, driven by one
6-K
EX-99.1
SNY
Sanofi
25 Apr 24
Sales growth of 6.7% at CER and business EPS(1) of €1.78
10:49am
million, led by Nexviazyme and ALTUVIIIO
Vaccines sales up 5.6%, boosted by Beyfortus
Consumer Healthcare (CHC) up 9.0%, benefiting from the Qunol … at: https://www.sanofi.com/en/our-science/our-pipeline.
Consumer Healthcare
Net sales (€ million)
Q1 2024
Change
at CER
Seasonal symptoms & pain relief
F-3ASR
2a1qg4 ar
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
6-K
EX-99.1
tgalsv1tjzl6uox7h
20 Mar 24
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
2:07pm
6-K
EX-99.1
1u2yveruf wg
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.4
komrn4 tgud
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.2
yopeo5xbgl7n3p3y 5c
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.3
o27pu5aot3vtj7p1
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.5
w2p7k20 v06cx3b6uo
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.1
n2jut1qx1w5l
15 Feb 24
Current report (foreign)
12:09pm
6-K
EX-99.1
div2mnr6t70 pt0
2 Feb 24
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
1:21pm
6-K
EX-99.2
sad 34m702jj8skeqi
2 Feb 24
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
1:21pm
6-K
EX-99.1
qrqbu
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
6-K
EX-99.1
lbjup7rwqtzy1
23 Jan 24
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
7:23am
6-K
EX-99.1
jf5zbajp
17 Jan 24
Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee
1:49pm
6-K
EX-99.1
npcnj 84g
27 Dec 23
Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
11:18am
6-K
EX-99.4
itld71j9h 9vbmg
20 Dec 23
Current report (foreign)
10:39am